Century Therapeutics (IPSC) Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IPSC shares.
View IPSC analyst ratings or view top-rated stocks.

8 Wall Street research analysts have issued 1-year price targets for Century Therapeutics' stock. Their IPSC share price forecasts range from $5.00 to $28.00. On average, they predict the company's stock price to reach $15.33 in the next twelve months. This suggests a possible upside of 651.6% from the stock's current price.
View analysts price targets for IPSC or view top-rated stocks among Wall Street analysts.

Century Therapeutics' stock was trading at $5.13 at the beginning of the year. Since then, IPSC stock has decreased by 60.2% and is now trading at $2.04.
View the best growth stocks for 2023 here.

Century Therapeutics saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 642,200 shares, a drop of 14.0% from the August 15th total of 747,100 shares. Based on an average daily trading volume, of 100,600 shares, the days-to-cover ratio is currently 6.4 days. Approximately 2.7% of the company's shares are sold short.
View Century Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our IPSC earnings forecast.

Century Therapeutics, Inc. (NASDAQ:IPSC) posted its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.54) by $0.02. The firm earned $0.10 million during the quarter, compared to analyst estimates of $1.54 million. Century Therapeutics had a negative net margin of 2,782.34% and a negative trailing twelve-month return on equity of 43.88%.

(IPSC) raised $201 million in an IPO on Friday, June 18th 2021. The company issued 10,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.

Century Therapeutics trades on the NASDAQ under the ticker symbol "IPSC."

Century Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.71%), State Street Corp (0.76%), Geode Capital Management LLC (0.74%), Northern Trust Corp (0.30%), Charles Schwab Investment Management Inc. (0.27%) and New York Life Investment Management LLC (0.20%). Insiders that own company stock include Eli Casdin, Luis Borges and Versant Venture Capital Vi, L.
View institutional ownership trends.

Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IPSC stock can currently be purchased for approximately $2.04.

Century Therapeutics (NASDAQ:IPSC) has a market capitalization of $121.91 million and generates $5.20 million in revenue each year. The company earns $-130,930,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis.

The company employs 163 workers across the globe.

The official website for the company is www.centurytx.com. The company can be reached via phone at 267-817-5790 or via email at investor.relations@centurytx.com.